Clinical trials: Adalimumab
Crohn's Disease
A Study of Subcutaneous HUMIRA (Adalimumab) Injection to Assess Adverse Events and Change in Disease Activity In Adult Participants With Moderate to Severe Active Crohn's Disease (CD)
Crohn's disease (CD) is an incurable chronic inflammatory disorder of the gastrointestinal tract. This study will assess how safe and effective Humira (adalimumab) is in treating moderately to severely active CD in China.
- Trial name
- NCT05394805
- Where
- 10 sites in China
- Volunteers
- 156 people
- Sponsor
- AbbVie
Ankylosing Spondylitis
A Study of Adalimumab in Japanese Subjects With Active Ankylosing Spondylitis
To evaluate efficacy, safety and pharmacokinetics of adalimumab in Japanese subjects with active ankylosing spondylitis
- Trial name
- NCT00667355
- Testing
- adalimumab
- Where
- 19 sites in Japan
- Volunteers
- 41 people
- Sponsor
- Abbott
Crohn's Disease
Study of Adalimumab Treatment for Induction and Maintenance of Clinical Remission in Subjects With Crohn's Disease
The purpose of this study is to evaluate the safety of adalimumab for treatment of patients with moderate to severe Crohn's Disease (CD) and to measure the effects of treatment on patient general well-being, health-related…
- Trial name
- NCT00409617
- Testing
- adalimumab
- Where
- 189 sites in Austria, Belgium and 15 more
- Volunteers
- 945 people
- Sponsor
- Abbott
Rheumatoid Arthritis
A 3-year Study Following up Patients With Moderate to Severe Rheumatoid Arthritis Treated With Humira in Greece
The objectives of the study are to observe and assess the long-term use, safety and efficacy of Humira (adalimumab), as prescribed by the rheumatologist in a normal clinical setting and in accordance with the terms of the…
- Trial name
- NCT01086033
- Where
- 60 sites in Greece
- Volunteers
- 566 people
- Sponsor
- AbbVie (prior sponsor, Abbott)
Crohn's Disease
Long-term Safety and Tolerability Study of Adalimumab in Subjects With Crohn's Disease
To evaluate the long-term maintenance of response, safety and tolerability of repeated administration of adalimumab in subjects with Crohn's disease who participated in and successfully completed Protocol M02-404 or Protocol…
- Trial name
- NCT00195715
- Testing
- Adalimumab
- Where
- 111 sites in United States, Australia and 13 more
- Volunteers
- 777 people
- Sponsor
- Abbott
Psoriatic Arthritis
Safety and Efficacy Study of Adalimumab in Patients With Active Psoriatic Arthritis (PsA)
The purpose of the study is to assess the safety and clinical efficacy of adalimumab in active psoriatic arthritis (PsA) subjects when adalimumab is added to insufficient standard therapy including patients that have failed other…
- Trial name
- STEREO (NCT00235885)
- Testing
- adalimumab
- Where
- United States
- Volunteers
- 445 people
- Sponsor
- Abbott
Psoriasis
Efficacy and Safety of Adalimumab in Subjects With Moderate to Severe Chronic Plaque Psoriasis
A Phase III, Multicenter Study of the Efficacy and Safety of Adalimumab Treatment in Subjects with Moderate to Severe Chronic Plaque Psoriasis
- Trial name
- NCT00237887
- Testing
- adalimumab
- Volunteers
- 1,212 people
- Sponsor
- Abbott
Rheumatoid Arthritis
A Study to Compare Efficacy and Safety of CT-P17 With Humira in Patients With Active Rheumatoid Arthritis
This is a Phase III Study to Compare Efficacy and Safety of CT-P17 with Humira in Patients With Active Rheumatoid Arthritis
- Trial name
- NCT03789292
- Testing
- CT-P17 SC, Humira SC
- Where
- Bulgaria
- Volunteers
- 648 people
- Sponsor
- Celltrion
Moderate to Severe Plaque Psoriasis
Effectiveness of Adalimumab in Moderate to Severe Plaque Psoriasis Patients With Distinct Co-morbidities
This multicenter, post marketing observational study (PMOS) was designed to evaluate the effectiveness of adalimumab over a period of 9 months as determined by the Psoriasis Area and Severity Index (PASI) in participants with…
- Trial name
- EPIC (NCT01401452)
- Volunteers
- 246 people
- Sponsor
- AbbVie (prior sponsor, Abbott)
Moderate Chronic Plaque Psoriasis, Severe Chronic Plaque Psoriasis
Hulio Interchangeability to Humira®, Comparing Pharmacokinetics, Efficacy, Safety and Immunogenicity
Hulio is a monoclonal antibody currently approved as a biosimilar to European Union approved and United States (US)-Licensed Humira.
- Trial name
- NCT05637515
- Testing
- Humira 40 MG in Prefilled Syringe, Hulio 40 MG in Prefilled Syringe / Humira 40 MG in Prefilled Syringe
- Where
- 36 sites in Bulgaria, Czechia and 2 more
- Volunteers
- 374 people
- Sponsor
- Biocon Biologics Inc.
Pediatric Crohn's Disease
Post-Marketing Surveillance of Humira in Korean Pediatric Crohn's Disease (CD) Patients Under the "New-Drug Re-examination"
This study is a non-interventional, observational study of Humira® in the treatment of pediatric CD as per the New Drug Re-examination Guideline in Korea.
- Trial name
- NCT02578238
- Volunteers
- 143 people
- Sponsor
- AbbVie
Ulcerative Colitis
Impact of Adalimumab on Patient-reported Outcomes in Ulcerative Colitis
To evaluate the real-life effect after 1 year of adalimumab treatment on psychological distress/depression symptoms in moderate-to-severe Ulcerative Colitis (UC) patients.
- Trial name
- UCanADA (NCT02506179)
- Where
- 23 sites in Canada
- Volunteers
- 100 people
- Sponsor
- AbbVie
Rheumatoid Arthritis
A Phase 3 Study Comparing 2 Doses Of CP-690,550 And The Active Comparator, Humira (Adalimumab) Vs. Placebo For Treatment Of Rheumatoid Arthritis
This is a comparative study of CP 690,550, Humira (adalimumab) and placebo on background methotrexate in patients with Rheumatoid Arthritis.
- Trial name
- NCT00853385
- Testing
- CP 690,550, CP-690,550, Biologic TNFi
- Where
- 125 sites in United States, Australia and 19 more
- Volunteers
- 717 people
- Sponsor
- Pfizer
AS
Efficacy and Safety of IBI303 in Adult Patients With Active Ankylosing Spondylitis
Study of the efficacy and safety of IBI303 compared with adalimumab in adult patients with ankylosing spondylitis (AS) who have had an inadequate response to or who are intolerant to one or more nonsteroidal anti-inflammatory…
- Trial name
- NCT02893254
- Testing
- IBI303, Adalimumab
- Volunteers
- 438 people
- Sponsor
- Innovent Biologics (Suzhou) Co. Ltd.
Rheumatoid Arthritis
Rheumatoid Arthritis Satisfaction Outcome Research
RA satisfaction OR: This study aim to compare treatment satisfaction and quality of life between patients who have been using tofacitinib citrate and patients who have been using adalimumab for 6 months or more and less than 2…
- Trial name
- NCT03703817
- Where
- 23 sites in South Korea
- Volunteers
- 421 people
- Sponsor
- Pfizer
Moderate to Severe Ulcerative Colitis
Fecal Calprotectin Levels, Quality of Life, and Workability in Patients Suffering From Ulcerative Colitis Under Adalimumab Therapy - AdaProQuo
The objectives of this study are to explore the fecal calprotectin (fC) levels of UC patients under adalimumab therapy and the correlation with their general wellbeing (Quality of Life [QoL]), workability, and disease activity.
- Trial name
- AdaProQuo (NCT02092389)
- Volunteers
- 10 people
- Sponsor
- AbbVie
Crohn's Disease
Remission in Subjects With Crohn's Disease, 1 Year Phase
The objectives were: (1) To demonstrate the efficacy of adalimumab in the maintenance of clinical remission up to 56 weeks in participants with Crohn's disease who participated in NCT00055523; (2) To delineate the safety of…
- Trial name
- CLASSICII (NCT00055497)
- Testing
- DB adalimumab 40 mg eow, DB adalimumab 40 mg ew, OL adalimumab 40 mg
- Where
- 43 sites in United States
- Volunteers
- 276 people
- Sponsor
- Abbott
Plaque Psoriasis
Comparison of CHS-1420 Versus Humira in Subjects With Chronic Plaque Psoriasis
This is a 3-period study comparing CHS-1420 to Humira in patients with chronic plaque psoriasis.
- Trial name
- PsOsim (NCT02489227)
- Testing
- CHS-1420, Adalimumab
- Where
- 99 sites in United States, Bulgaria and 14 more
- Volunteers
- 545 people
- Sponsor
- Coherus Oncology, Inc.
Rheumatoid Arthritis (RA)
Changes in Ultrasonographic Assessment of Inflammation Upon Initiation of Adalimumab Combination Therapy in Chinese Rheumatoid Arthritis (RA) Patients With Inadequate Response to Methotrexate
Prospective, post-marketing, multi-center, open-label study to explore if the initiation of adalimumab could influence grey-scale (GS) and power Doppler (PD) ultrasonographic (US) score using 36-joint plus 4-tendon scoring…
- Trial name
- NCT02786563
- Where
- 4 sites in China
- Sponsor
- AbbVie
Ankylosing Spondylitis
Human Anti-tumor Necrosis Factor (TNF) Monoclonal Antibody Adalimumab in Subjects With Active Ankylosing Spondylitis
The objective of this study was to evaluate the safety and efficacy of adalimumab 40 mg given every other week (eow) in subjects with active ankylosing spondylitis (AS) who have had an inadequate response to, or who are…
- Trial name
- ATLAS (NCT00085644)
- Testing
- adalimumab (D2E7)
- Where
- 22 sites in United States
- Volunteers
- 315 people
- Sponsor
- Abbott